LI YISHAN enters BLOSSOMHILL THERAPEUTICS, INC. with 2.13M shares plus derivative instruments
Holding both equity and derivatives at entry signals strong long-term conviction in the company.
Direct Indirect Derivatives
Filed: 8/7/2026ACC: 0001772233-26-000004
DirectorOfficer10% Owner· Executive Chairman
Since Aug 2026
2.13M
Baseline shares
50% direct
1.07M
Direct ownership
1 position
1.84M
Derivative underlying
3 instruments
2
Security positions
1.07M indirect
Non-Derivative Holdings2
Common Stock
IndirectShares owned1.07M
Common Stock
DirectShares owned1.07M
Total
1.07M direct·1.07M indirect2.13M
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 1.07M | Indirect |
| Common Stock | 1.07M | Direct |
| Total | 2.13M | 1.07M direct·1.07M indirect |
Derivative Holdings3
Series B Preferred Stock
IndirectUnderlying security
Common Stock
Underlying shares
124.78K
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Series B Preferred Stock
IndirectUnderlying security
Common Stock
Underlying shares
113.44K
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Series Angel Preferred Stock
IndirectUnderlying security
Common Stock
Underlying shares
1.60M
Shares owned
N/A
Exercise price
Expiration
—
Exercise window
—
Total
Underlying
1.84M
Owned
0.00
| Security | Underlying | Exercise Price | Exercise Window | Expiration | Underlying Shares | Shares Owned |
|---|---|---|---|---|---|---|
| Series B Preferred Stock Indirect | Common Stock | — | — | 124.78K | N/A | |
| Series B Preferred Stock Indirect | Common Stock | — | — | 113.44K | N/A | |
| Series Angel Preferred Stock Indirect | Common Stock | — | — | 1.60M | N/A | |
| Total | 1.84M | 0.00 | ||||